Updated 2011 safety review of GLP-1 receptor agonists: GI side effects (nausea, vomiting) are most common but diminish over time; pancreatitis and thyroid concerns addressed with monitoring recommendations.
Key findingUpdated 2011 safety review of GLP-1 receptor agonists: GI side effects (nausea, vomiting) are most common but diminish over time; pancreatitis and thy
What the researchers found
Updated 2011 safety review of GLP-1 receptor agonists: GI side effects (nausea, vomiting) are most common but diminish over time; pancreatitis and thyroid concerns addressed with monitoring recommendations.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
Diabetes/metabolism research and reviews, 27(6), 528-42
Citation
Aroda, Vanita R; Ratner, Robert. (2011). The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.. Diabetes/metabolism research and reviews, 27(6), 528-42. https://doi.org/10.1002/dmrr.1202